First-Line Therapy in Ovarian Cancer Trials

International Journal of Gynecological Cancer - Tập 21 Số 4 - Trang 756-762 - 2011
Tate Thigpen1, Andreas duBois2, Jessica N. McAlpine3, Philip J. DiSaia4, Keiichi Fujiwara5, William J. Hoskins6, Gunnar B. Kristensen7, Robert S. Mannel4, Maurie Markman8, Jacobus Pfisterer2, Michael Quinn9, Nick Reed2,3, Ann Marie Swart2,3, Jonathan S. Berek10, Nicoletta Colombo11, Gilles Freyer12, Dolores Gallardo13, Marie Plante3, Andrés Poveda14, Larry Rubinstein6, Monica Bacon15, Henry C Kitchener2,3, Gavin Stuart3
1MD, PhD, Division of Oncology, University of Mississippi School of Medicine, Jackson, MS 39216. E-mail: jtthigpen{at}att.net.
2AGO-OVAR (Germany)
3NCIC-CTG (Canada)
4GOG
5JGOG (Japan)
6NCI
7NSGO (Scandinavia)
8SWOG
9ANZGOG (Australia–New Zealand)
10COGI
11MaNGO, Italy
12GINECO (France)
13GICOM, Mexico
14GEICO, Spain;
15GCIG;

Tóm tắt

At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients.A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)?A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials?A3: Is the 2004 GCIG-recommended standard comparator arm still valid?A4: What is the role of modifying dose, schedule, and delivery of chemotherapy?A5: What role does surgery play today?

Từ khóa


Tài liệu tham khảo

Gordon, 2001, J Clin Oncol, 19, 3312, 10.1200/JCO.2001.19.14.3312

Bookman, 1998, J Clin Oncol, 16, 3345, 10.1200/JCO.1998.16.10.3345

Shapiro, 1996, Gynecol Oncol, 63, 89, 10.1006/gyno.1996.0284

Rose, 1998, J Clin Oncol, 16, 405, 10.1200/JCO.1998.16.2.405

Markman, 2006, Gynecol Oncol, 101, 436, 10.1016/j.ygyno.2005.10.036

Rose, 2003, Gynecol Oncol, 88, 130, 10.1016/S0090-8258(02)00091-4

Bajetta, 1996, J Clin Oncol, 14, 2546, 10.1200/JCO.1996.14.9.2546

Markman, 1992, J Clin Oncol, 10, 243, 10.1200/JCO.1992.10.2.243

Look, 1995, Am J Clin Oncol, 18, 19, 10.1097/00000421-199502000-00004

Markman, 1998, Gynecol Oncol, 69, 226, 10.1006/gyno.1998.5016

Miller, 2009, J Clin Oncol, 27, 2686, 10.1200/JCO.2008.19.2963

Ten Bokkel Huinink, 2009, J Clin Oncol, 27, 3097, 10.1200/JCO.2008.20.4826

Kavanagh, 2008, Int J Gynecol Cancer, 18, 460, 10.1111/j.1525-1438.2007.01053.x

Vergote, 2010, J Clin Oncol, 28, 393s, 10.1200/JCO.2010.28.7342

Naumann, 2010, J Clin Oncol, 28, 952s, 10.1200/jco.2010.28.18_suppl.lba5012b

Burger, 2007, J Clin Oncol, 25, 5165, 10.1200/JCO.2007.11.5345

Markman, 1996, Gynecol Oncol, 62, 4, 10.1006/gyno.1996.0181

Matei, 2008, J Clin Oncol, 26, 301s, 10.1200/jco.2008.26.15_suppl.5537

Behbakht, 2010, Gynecol Oncol, 116, S5

Matulonis, 2009, J Clin Oncol, 27, 5601, 10.1200/JCO.2009.23.2777

Audeh, 2010, Lancet, 376, 235, 10.1016/S0140-6736(10)60893-8

Omura, 1986, Cancer, 57, 1725, 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J

Muggia, 2000, J Clin Oncol, 18, 106, 10.1200/JCO.2000.18.1.106

Thông tin
Thông tin xuất bản

International Journal of Gynecological Cancer

Tập 21 Số 4

756-762

Thông tin tác giả